Does topical capsaicin provide pain relief for patients suffering from chronic neuropathic pain?

2019 ◽  
Vol 22 (5) ◽  
pp. 1-1
Author(s):  
James Breen ◽  
Hannah Schrubbe ◽  
Shayna Smallwood
Keyword(s):  
Neuropathic Pain ◽  
Pain Relief ◽  
Chronic Neuropathic Pain ◽  
Provide Pain Relief ◽  
Topical Capsaicin

scholarly journals Pulsed Radiofrequency of Stellate Ganglion for Neuropathic Pain Associated with Recurrent Pleural Leiomyosarcoma - A Case Report

2021 ◽  
Vol 0 ◽  
pp. 1-3
Author(s):  
Anand Murugesan ◽  
M. S. Raghuraman
Keyword(s):  
Neuropathic Pain ◽  
Case Report ◽  
Soft Tissue ◽  
Pain Relief ◽  
Stellate Ganglion ◽  
Soft Tissue Sarcomas ◽  
Pulsed Radiofrequency ◽  
Chronic Neuropathic Pain ◽  
Provide Pain Relief

Pleural leiomyosarcomas are rare soft-tissue sarcomas. Neuropathic pain associated with such tumours can be quite debilitating. We present the case of a 62-year-old woman with chronic neuropathic pain refractory to pharmacologic interventions in association with recurrent pleural leiomyosarcoma. Pulsed radio-frequency of the stellate ganglion was performed after due consideration and planning as a palliative measure to provide pain relief. The patient was discharged the same day with pain score 0/10 and followed up for 3 years. The unique features of this case report are: (1) Different approach of the treatment modality and (2) longer follow-up.

scholarly journals Topical capsaicin (high concentration) for chronic neuropathic pain in adults

2013 ◽  
Author(s):  
Sheena Derry ◽  
Andrew S C Rice ◽  
Peter Cole ◽  
Toni Tan ◽  
R Andrew Moore
Keyword(s):  
Neuropathic Pain ◽  
High Concentration ◽  
Chronic Neuropathic Pain ◽  
Topical Capsaicin

scholarly journals Topical capsaicin for chronic neuropathic pain in adults

2009 ◽  
Author(s):  
Sheena Derry ◽  
Rosalind Lloyd ◽  
R Andrew Moore ◽  
Henry J McQuay
Keyword(s):  
Neuropathic Pain ◽  
Chronic Neuropathic Pain ◽  
Topical Capsaicin

scholarly journals Percutaneous peripheral nerve stimulation for the treatment of chronic neuropathic postamputation pain: a multicenter, randomized, placebo-controlled trial

2019 ◽  
Vol 44 (6) ◽  
pp. 637-645 ◽  
Author(s):  
Christopher Gilmore ◽  
Brian Ilfeld ◽  
Joshua Rosenow ◽  
Sean Li ◽  
Mehul Desai ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Pain Relief ◽  
Peripheral Nerve ◽  
Nerve Stimulation ◽  
Peripheral Nerve Stimulation ◽  
Pain Interference ◽  
Controlled Study ◽  
Chronic Neuropathic Pain ◽  
Postamputation Pain

Background and objectivesChronic neuropathic pain is a common challenging condition following amputation. Recent research demonstrated the feasibility of percutaneously implanting fine-wire coiled peripheral nerve stimulation (PNS) leads in proximity to the sciatic and femoral nerves for postamputation pain. A multicenter, double-blinded, randomized, placebo-controlled study collected data on the safety and effectiveness of percutaneous PNS for chronic neuropathic pain following amputation.MethodsTwenty-eight lower extremity amputees with postamputation pain were enrolled. Subjects underwent ultrasound-guided implantation of percutaneous PNS leads and were randomized to receive PNS or placebo for 4 weeks. The placebo group then crossed over and all subjects received PNS for four additional weeks. The primary efficacy endpoint evaluated the proportion of subjects reporting ≥50% pain reduction during weeks 1–4.ResultsA significantly greater proportion of subjects receiving PNS (n=7/12, 58%, p=0.037) demonstrated ≥50% reductions in average postamputation pain during weeks 1–4 compared with subjects receiving placebo (n=2/14, 14%). Two subjects were excluded from efficacy analysis due to eligibility changes. Significantly greater proportions of PNS subjects also reported ≥50% reductions in pain (n=8/12, 67%, p=0.014) and pain interference (n=8/10, 80%, p=0.003) after 8 weeks of therapy compared with subjects receiving placebo (pain: n=2/14, 14%; pain interference: n=2/13, 15%). Prospective follow-up is ongoing; four of five PNS subjects who have completed 12-month follow-up to date reported ≥50% pain relief.ConclusionsThis work demonstrates that percutaneous PNS therapy may provide enduring clinically significant pain relief and improve disability in patients with chronic neuropathic postamputation pain.Trial registration numberNCT01996254.

scholarly journals Erectile Dysfunction as Rare Side Effect in the Simultaneous Intrathecal Application of Morphine and Clonidine

2012 ◽  
Vol 4;15 (4;8) ◽  
pp. E523-E526
Author(s):  
Gershom Koman
Keyword(s):  
Erectile Dysfunction ◽  
Pain Relief ◽  
Side Effect ◽  
Life Quality ◽  
Chronic Neuropathic Pain ◽  
Combined Application ◽  
Rare Side Effect ◽  
Provide Pain Relief ◽  
History Of ◽  
Systemic Application

We report on the case of a 52-year-old man who presented with a history of chronic neuropathic pain treated with intrathecal application of morphine for many years. In spite of significant dose escalation, considerable pain relief had not been achieved. Ziconotide had been tried but not only did it not provide pain relief, but it also caused severe side effects in this patient. A combination of morphine and clonidine was delivered by a programmable pump, slowly increasing the clonidine rate over several weeks. For ease of transition and minimization of hospitalization, which was a special concern to this patient, combining clonidine and morphine was chosen over monotherapy with hydromorphone, with both possibilities being described as equal alternatives in the literature. Considerable pain relief was achieved during week 2 at a clonidine dose of 0.040 mg/d, thereby decreasing the visual analog score (VAS) from 10 to 4. Yet, after developing erectile dysfunction and relative hypotension soon after beginning clonidine treatment, the patient decided not to continue with the combined application of morphine and clonidine. Treatment was therefore switched back to the former monotherapy with morphine. Thereafter, erectile dysfunction disappeared and blood pressure returned to habitual high levels. Although common in systemic application, erectile dysfunction caused by the intrathecal application of clonidine has not been described yet in the literature. In this patient, this rare side effect decisively impaired life quality, subjectively outweighing the considerable pain relief which could be achieved after formerly inefficacious treatment. Further and prospective investigation might be needed to estimate the connection of erectile dysfunction to intrathecal application of clonidine. Key words: intrathecal, erectile dysfunction, morphine, chronic pain, drug pump

Sign in / Sign up

Export Citation Format

Share Document